A Non-randomized, Open-label, Prospective, Multicenter Study of Apatinib Mesylate Tablet as Second-line and Later Therapy in Patients With Extensive Stage Small Cell Lung Cancer
Phase of Trial: Phase IV
Latest Information Update: 10 Sep 2019
Price : $35 *
At a glance
- Drugs Rivoceranib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 10 Sep 2019 Results (n=36) presented at the 20th World Conference on Lung Cancer.
- 08 Mar 2018 Status changed from not yet recruiting to recruiting.
- 22 Dec 2017 New trial record